Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| GCR-M5254 | Mouse | Mouse GCGR / Glucagon receptor Protein, Fc Tag |  |
|
|
| GCR-H52H3 | Human | Human GCGR / Glucagon receptor Protein, His Tag (MALS verified) |  |
|
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Glucagon (rDNA origin, Lilly) | Approved | Eli Lilly And Company | Glucagon | United States | Hypoglycemia | Eli Lilly And Company | 1998-09-11 | Diabetes Mellitus, Type 1; Hypoglycemia | Details | |
| Glucagon (Xeris Pharmaceuticals) | Approved | Xeris Pharmaceuticals | Gvoke | United States | Hypoglycemia | Xeris Pharmaceuticals Inc | 1960-01-01 | Hypoglycemia; Hyperinsulinism | Details | |
| Glucagon (rDNA origin, Novo Nordisk) | GL-G | Approved | Novo Nordisk A/S | GlucaGen, Glucagon G | Japan | Hypoglycemia | Novo Nordisk A/S | 1998-06-22 | Hypoglycemia | Details |
| Glucagon intranasal (Eli Lilly/Locemia Solutions) | AMG504-1; LY-900018 | Approved | Amg Medical, Locemia Solutions | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus | Details | |||||
| Dasiglucagon | ZP-GA-1; ZP-4207 | Approved | Zealand Pharma A/S | ZEGALOGUE | United States | Hypoglycemia | Zealand Pharma, Zealand Pharma A/S | 2021-03-22 | Diabetes Mellitus, Type 1; Congenital Hyperinsulinism; Hypoglycemia; Glucose Metabolism Disorders | Details |
| Glucagon | MP-123456B | Approved | Eli Lilly And Company | Baqsimi, Ogluo | EU | Diabetes Mellitus | Eli Lilly Nederland Bv | 1960-11-14 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| HM-15136 | HM-15136 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Congenital Hyperinsulinism; Diabetes Mellitus, Type 2; Hyperinsulinism | Details |
| PRT-003 | PRT-003 | Phase 1 Clinical | Particle Therapeutics | Details | |
| SAR-441255 | SAR-441255 | Phase 1 Clinical | Sanofi | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) | Phase 1 Clinical | Translational Research Institute For Metabolism And Diabetes | Obesity | Details | |
| NN-9513 (Novo Nordisk) | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus | Details | |
| Isosteviol | ISV; STX-03 | Phase 2 Clinical | Stevia Pharma | Diabetes Mellitus, Type 2 | Details |
| IONIS-GCGRRx | ISISGCGRRx; ISIS-449884; IONIS-GCGRRx | Phase 2 Clinical | Ionis | Diabetes Mellitus, Type 2 | Details |
| volagidemab | AMG-477; REMD-477 | Phase 2 Clinical | Amgen Inc | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus | Details |
| BioChaperone Glucagon | BC Glucagon | Phase 1 Clinical | Adocia | Diabetes Mellitus, Type 1; Hypoglycemia | Details |
| NN-9277 | NN-9277; NNC-9204-1177 | Phase 1 Clinical | Novo Nordisk A/S | Obesity; Overweight | Details |
| Oxyntomodulin (Xenetic Biosciences) | Phase 2 Clinical | Pharmsynthez, Xenetic Biosciences | Diabetes Mellitus, Type 2; Obesity | Details | |
| Pegapamodutide | TT-401; OPK-88003; LY-2944876; WG4ID2U7FT | Phase 2 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Obesity | Details |
| LGD-6972 | LGD-6972; MB-11262; RVT-1502 | Phase 2 Clinical | Ligand Pharmaceuticals Inc | Diabetes Mellitus, Type 2 | Details |
| ZP-2929 | ZP-2929 | Phase 1 Clinical | Zealand Pharma A/S | Diabetes Mellitus, Type 2; Obesity | Details |
| PRT-001 | PRT-001 | Phase 3 Clinical | Particle Therapeutics | Hypoglycemia | Details |
| Cotadutide | MEDI-0382 | Phase 2 Clinical | Medimmune Llc | Diabetes Mellitus, Type 2; Renal Insufficiency; Non-alcoholic Fatty Liver Disease; Obesity; Renal Insufficiency, Chronic | Details |
| HM-15211 | HM-15211 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Non-alcoholic Fatty Liver Disease; Obesity | Details |
| LY-3305677 | OXM-3; IBI-362; LY-3305677 | Phase 2 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| BI-456906 | BI-456906 | Phase 2 Clinical | Zealand Pharma A/S | Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| Efinopegdutide | JNJ-5111; HM-12525A; JNJ-64565111 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Obesity; Kidney Failure, Chronic | Details |
This web search service is supported by Google Inc.
A-Z